Trial · NCT02706886
Results by group198
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 198
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 1.0 mg/kg | Day 1 | 1.5000 | Full Range 0.517 to 8.000 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 3.0 mg/kg | Day 1 | 3.0000 | Full Range 0.500 to 8.000 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part A: SAD: Lumasiran 6.0 mg/kg | Day 1 | 7.0000 | Full Range 0.500 to 8.067 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 1 | 3.9917 | Full Range 0.567 to 5.967 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 1 | 4.9917 | Full Range 0.533 to 12.000 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 1 | 9.0000 | Full Range 5.783 to 12.017 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 57 | 3.0417 | Full Range 0.500 to 6.000 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 57 | 2.9833 | Full Range 0.500 to 8.000 | hours |
| Time to Cmax (Tmax) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 85 | 5.9833 | Full Range 4.050 to 7.950 | hours |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part A: SAD: Lumasiran 0.3 mg/kg | Day 1 | 293.5232 | Standard Deviation 96.86989 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part A: SAD: Lumasiran 1.0 mg/kg | Day 1 | 1899.8119 | Standard Deviation 558.25326 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part A: SAD: Lumasiran 3.0 mg/kg | Day 1 | 7211.5890 | Standard Deviation 1125.64173 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part A: SAD: Lumasiran 6.0 mg/kg | Day 1 | 16778.0579 | Standard Deviation 4380.15325 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 1 | 1428.0412 | Standard Deviation 697.85233 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 1 | 7400.2181 | Standard Deviation 2331.89843 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 1 | 6337.9082 | Standard Deviation 3840.03340 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 1.0 mg/kg qM | Day 57 | 1608.1457 | Standard Deviation 708.95156 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg qM | Day 57 | 7959.7873 | Standard Deviation 1726.57675 | h*ng/mL |
| Area Under the Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUC0-last) of Lumasiran in Plasma | Part B: MAD: Lumasiran 3.0 mg/kg q3M | Day 85 | 5136.3462 | Standard Deviation 2757.90139 | h*ng/mL |
| Terminal Half-life (t1/2) of Lumasiran in Plasma | Part A: SAD: Lumasiran 1.0 mg/kg | Day 1 | 7.0655 | Standard Deviation 0.37379 | hours |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02706886/results?page=2